| Year |
Citation |
Score |
| 2022 |
Kang KD, Bernstock JD, Totsch SK, Gary SE, Rocco A, Nan L, Li R, Etminan T, Han X, Beierle EA, Eisemann T, Wechsler-Reya RJ, Bae S, Whitley R, Gillespie GY, Markert JM, et al. Safety and efficacy of intraventricular immunovirotherapy with oncolytic HSV-1 for CNS cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36239623 DOI: 10.1158/1078-0432.CCR-22-1382 |
0.312 |
|
| 2022 |
Ghajar-Rahimi G, Kang KD, Totsch SK, Gary S, Rocco A, Blitz S, Kachurak K, Chambers MR, Li R, Beierle EA, Bag A, Johnston JM, Markert JM, Bernstock JD, Friedman GK. Clinical advances in oncolytic virotherapy for pediatric brain tumors. Pharmacology & Therapeutics. 239: 108193. PMID 35487285 DOI: 10.1016/j.pharmthera.2022.108193 |
0.318 |
|
| 2022 |
Quinn CH, Beierle AM, Hutchins SC, Marayati R, Bownes LV, Stewart JE, Markert HR, Erwin MH, Aye JM, Yoon KJ, Friedman GK, Willey CD, Markert JM, Beierle EA. Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy. Cancers. 14. PMID 35159029 DOI: 10.3390/cancers14030762 |
0.31 |
|
| 2021 |
Travis RL, Marcrom SR, Brown MH, Patel MP, Markert JM, Riley KO, Conry R, Willey CD, Bredel M, Fiveash JB. Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition. Advances in Radiation Oncology. 6: 100561. PMID 33665483 DOI: 10.1016/J.Adro.2020.08.017 |
0.307 |
|
| 2020 |
Chambers MR, Bentley RT, Crossman DK, Foote JB, Koehler JW, Markert JM, Omar NB, Platt SR, Self DM, Shores A, Sorjonen DC, Waters AM, Yanke AB, Gillespie GY. The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas. Frontiers in Surgery. 7: 59. PMID 33005623 DOI: 10.3389/Fsurg.2020.00059 |
0.44 |
|
| 2020 |
Bastola S, Pavlyukov MS, Yamashita D, Ghosh S, Cho H, Kagaya N, Zhang Z, Minata M, Lee Y, Sadahiro H, Yamaguchi S, Komarova S, Yang E, Markert J, Nabors LB, et al. Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy. Nature Communications. 11: 4660. PMID 32938908 DOI: 10.1038/S41467-020-18189-Y |
0.386 |
|
| 2020 |
Si Y, Kim S, Ou J, Lu Y, Ernst P, Chen K, Whitt J, Carter AM, Markert JM, Bibb JA, Chen H, Zhou L, Jaskula-Sztul R, Liu XM. Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy. Cancer Gene Therapy. PMID 32684623 DOI: 10.1038/S41417-020-0196-5 |
0.341 |
|
| 2020 |
Bernstock JD, Bag A, Fiveash J, Kachurak K, Elsayed G, Chagoya G, Gessler F, Valdes PA, Madan-Swain A, Whitley R, Markert J, Gillespie Y, Johnston JM, Friedman GK. Design and Rationale for First-In-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors. Human Gene Therapy. PMID 32657154 DOI: 10.1089/Hum.2020.101 |
0.47 |
|
| 2020 |
Marcrom SR, Foreman PM, Colvin TB, McDonald AM, Kirkland RS, Popple RA, Riley KO, Markert JM, Willey CD, Bredel M, Fiveash JB. Focal Management of Large Brain Metastases and Risk of Leptomeningeal Disease. Advances in Radiation Oncology. 5: 34-42. PMID 32051888 DOI: 10.1016/J.Adro.2019.07.016 |
0.337 |
|
| 2019 |
Bernstock JD, Vicario N, Rong L, Valdes PA, Choi BD, Chen JA, DiToro D, Osorio DS, Kachurak K, Gessler F, Johnston JM, Atkinson TP, Whitley RJ, Bag AK, Gillespie GY, ... Markert JM, et al. A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition. Oncoimmunology. 8: e1678921. PMID 31741780 DOI: 10.1080/2162402X.2019.1678921 |
0.41 |
|
| 2019 |
Ibrahim AN, Yamashita D, Anderson JC, Abdelrashid M, Alwakeal A, Estevez-Ordonez D, Komarova S, Markert JM, Goidts V, Willey CD, Nakano I. Intratumoral spatial heterogeneity of BTK kinomic activity dictates distinct therapeutic response within a single glioblastoma tumor. Journal of Neurosurgery. 1-12. PMID 31628288 DOI: 10.3171/2019.7.Jns191376 |
0.331 |
|
| 2019 |
Kasten BB, Udayakumar N, Leavenworth JW, Wu AM, Lapi SE, McConathy JE, Sorace AG, Bag AK, Markert JM, Warram JM. Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. Theranostics. 9: 5085-5104. PMID 31410203 DOI: 10.7150/Thno.34415 |
0.321 |
|
| 2019 |
Totsch SK, Schlappi C, Kang KD, Ishizuka AS, Lynn GM, Fox B, Beierle EA, Whitley RJ, Markert JM, Gillespie GY, Bernstock JD, Friedman GK. Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance. Oncogene. PMID 31289361 DOI: 10.1038/S41388-019-0870-Y |
0.431 |
|
| 2019 |
Mooney J, Bernstock JD, Ilyas A, Ibrahim A, Yamashita D, Markert JM, Nakano I. Current approaches and challenges in the molecular therapeutic targeting of glioblastoma. World Neurosurgery. PMID 31152883 DOI: 10.1016/J.Wneu.2019.05.205 |
0.371 |
|
| 2019 |
Fathallah-Shaykh HM, DeAtkine A, Coffee E, Khayat E, Bag AK, Han X, Warren PP, Bredel M, Fiveash J, Markert J, Bouaynaya N, Nabors LB. Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study. Plos Medicine. 16: e1002810. PMID 31136584 DOI: 10.1371/Journal.Pmed.1002810 |
0.305 |
|
| 2019 |
Pearl TM, Markert JM, Cassady KA, Ghonime MG. Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors. Molecular Therapy Oncolytics. 13: 14-21. PMID 30997392 DOI: 10.1016/J.Omto.2019.03.001 |
0.426 |
|
| 2019 |
Bernstock JD, Vicario N, Li R, Nan L, Totsch SK, Schlappi C, Gessler F, Han X, Parenti R, Beierle EA, Whitley RJ, Aban I, Gillespie GY, Markert JM, Friedman GK. Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice. Cancer Gene Therapy. PMID 30918335 DOI: 10.1038/S41417-019-0091-0 |
0.401 |
|
| 2019 |
Minata M, Audia A, Shi J, Lu S, Bernstock J, Pavlyukov MS, Das A, Kim SH, Shin YJ, Lee Y, Koo H, Snigdha K, Waghmare I, Guo X, Mohyeldin A, ... ... Markert JM, et al. Phenotypic Plasticity of Invasive Edge Glioma Stem-like Cells in Response to Ionizing Radiation. Cell Reports. 26: 1893-1905.e7. PMID 30759398 DOI: 10.1016/J.Celrep.2019.01.076 |
0.332 |
|
| 2019 |
Yamashita D, Minata M, Yu H, Zhang S, Li C, Flanary V, Ghosh S, Lee Y, Cho H, Botta D, Guo X, Ozaki S, Yamaguchi S, Komarova S, Bastola S, ... Markert J, et al. TMIC-12. TUMOR EDGE-DESTINED CELLS IN GBM CELLS IN A CELL-INTRINSIC MECHANISM Neuro-Oncology. 21: vi249-vi249. DOI: 10.1093/Neuonc/Noz175.1046 |
0.409 |
|
| 2019 |
Cassady K, Miller K, Prasad N, Maric D, Bernstock J, Roth J, Barker N, Coleman J, Schieffer K, Leraas K, Miller A, Leavenworth J, Cutter G, Whitley R, Roizman B, ... Markert J, et al. ATIM-32. PREDICTORS OF IMPROVED SURVIVAL FOLLOWING ONCOLYTIC VIRUS TREATMENT IN PATIENTS WITH RECURRENT GLIOBLASTOMA: GENE EXPRESSION ANALYSIS FROM THE PHASE IB G207 CLINICAL TRIAL Neuro-Oncology. 21: vi8-vi8. DOI: 10.1093/Neuonc/Noz175.031 |
0.378 |
|
| 2018 |
Bernstock JD, Wright Z, Bag AK, Gessler F, Gillespie GY, Markert JM, Friedman GK, Johnston JM. Stereotactic Placement of Intratumoral Catheters for Continuous Infusion Delivery of HSV-1 G207 in Pediatric Malignant Supratentorial Brain Tumors. World Neurosurgery. PMID 30481622 DOI: 10.1016/J.Wneu.2018.11.122 |
0.4 |
|
| 2018 |
Friedman GK, Bernstock JD, Chen D, Nan L, Moore BP, Kelly VM, Youngblood SL, Langford CP, Han X, Ring EK, Beierle EA, Gillespie GY, Markert JM. Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. Scientific Reports. 8: 13930. PMID 30224769 DOI: 10.1038/S41598-018-32353-X |
0.423 |
|
| 2018 |
Yu H, Pavlyukov MS, Minata M, Zhang S, Bastola S, Markert J, Bhat K, Wang M, Nakano I. Tmic-16. Core-Like Tumor Cells Promote Malignance Of Glioblastoma Via Intercellular Crosstalk With Edge-Like Tumor Cells In A Hdac1-Cd109 Dependent Manner Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.1075 |
0.358 |
|
| 2018 |
Friedman G, Bag A, Madan-Swain A, Li R, Kachurak K, Osorio D, Hukin J, Martin A, Pastakia D, Karajannis M, Bernstock J, Fiveash J, Reddy A, Whitley R, Gillespie Y, Markert J, et al. IMMU-08. PHASE I TRIAL (NCT02457845) SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF IMMUNOVIROTHERAPY WITH HSV G207 IN CHILDREN WITH PROGRESSIVE MALIGNANT SUPRATENTORIAL BRAIN TUMORS Neuro-Oncology. 20: i100-i100. DOI: 10.1093/Neuonc/Noy059.324 |
0.359 |
|
| 2017 |
Foreman PM, Jackson BE, Singh KP, Romeo AK, Guthrie BL, Fisher WS, Riley KO, Markert JM, Willey CD, Bredel M, Fiveash JB. Postoperative radiosurgery for the treatment of metastatic brain tumor: Evaluation of local failure and leptomeningeal disease. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. PMID 29248376 DOI: 10.1016/J.Jocn.2017.12.009 |
0.395 |
|
| 2017 |
Ghonime MG, Jackson J, Shah A, Roth J, Li M, Saunders U, Coleman J, Gillespie GY, Markert JM, Cassady KA. Chimeric HCMV/HSV-1 and Δγ134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory. Translational Oncology. 11: 86-93. PMID 29216507 DOI: 10.1016/J.Tranon.2017.10.005 |
0.417 |
|
| 2017 |
Marcrom SR, McDonald AM, Thompson JW, Popple RA, Riley KO, Markert JM, Willey CD, Bredel M, Fiveash JB. Fractionated stereotactic radiation therapy for intact brain metastases. Advances in Radiation Oncology. 2: 564-571. PMID 29204523 DOI: 10.1016/J.Adro.2017.07.006 |
0.335 |
|
| 2017 |
Ring EK, Li R, Moore BP, Nan L, Kelly VM, Han X, Beierle EA, Markert JM, Leavenworth JW, Gillespie GY, Friedman GK. Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002. Molecular Therapy Oncolytics. 7: 27-36. PMID 29034313 DOI: 10.1016/J.Omto.2017.09.003 |
0.368 |
|
| 2017 |
Yin J, Markert JM, Leavenworth JW. Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy. Frontiers in Oncology. 7: 136. PMID 28695111 DOI: 10.3389/Fonc.2017.00136 |
0.382 |
|
| 2017 |
Cassady KA, Bauer DF, Roth J, Chambers MR, Shoeb T, Coleman J, Prichard M, Gillespie GY, Markert JM. Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates. Molecular Therapy Oncolytics. 5: 1-10. PMID 28345027 DOI: 10.1016/J.Omto.2017.02.001 |
0.301 |
|
| 2017 |
Waters AM, Johnston JM, Reddy AT, Fiveash J, Madan-Swain A, Kachurak K, Bag AK, Gillespie GY, Markert JM, Friedman GK. Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors. Human Gene Therapy. Clinical Development. 28: 7-16. PMID 28319448 DOI: 10.1089/Humc.2017.002 |
0.466 |
|
| 2017 |
Foreman PM, Friedman GK, Cassady KA, Markert JM. Oncolytic Virotherapy for the Treatment of Malignant Glioma. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 14: 333-344. PMID 28265902 DOI: 10.1007/S13311-017-0516-0 |
0.443 |
|
| 2017 |
Waters AM, Johnston JM, Reddy AT, Fiveash J, Madan-Swain A, Kachurak K, Bag AK, Gillespie GY, Markert JM, Friedman GK. Rationale and Design of a Phase I Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors. Human Gene Therapy. Clinical Development. PMID 28253733 DOI: 10.1089/hum.2017.002 |
0.366 |
|
| 2017 |
Rudnick JD, Fink KL, Landolfi JC, Markert J, Piccioni DE, Glantz MJ, Swanson SJ, Gringeri A, Yu J. Immunological targeting of CD133 in recurrent glioblastoma: A multi-center phase I translational and clinical study of autologous CD133 dendritic cell immunotherapy. Journal of Clinical Oncology. 35: 2059-2059. DOI: 10.1200/Jco.2017.35.15_Suppl.2059 |
0.397 |
|
| 2017 |
Bag A, Li R, Gillespie Y, Markert J, Johnston J, Friedman GK. Pdct-23. Proliferation Index Influences Initial Response Pattern Of Pediatric High-Grade Gliomas Treated With Hsv-1 G207 Oncolytic Virotherapy. Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.764 |
0.41 |
|
| 2016 |
Fiveash JB, Arafat WO, Naoum GE, Guthrie BL, Sawrie SM, Spencer SA, Meredith RF, Markert JM, Conry RM, Nabors BL. A phase 2 study of radiosurgery and temozolomide for patients with 1 to 4 brain metastases. Advances in Radiation Oncology. 1: 83-88. PMID 28740873 DOI: 10.1016/J.Adro.2016.03.004 |
0.337 |
|
| 2016 |
Ring EK, Markert JM, Gillespie GY, Friedman GK. Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27836863 DOI: 10.1158/1078-0432.Ccr-16-1829 |
0.406 |
|
| 2016 |
Waters AM, Stafman LL, Garner EF, Mruthyunjayappa S, Stewart JE, Friedman GK, Coleman JM, Markert JM, Gillespie GY, Beierle EA. Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma. Translational Oncology. 9: 419-430. PMID 27751346 DOI: 10.1016/J.Tranon.2016.07.008 |
0.441 |
|
| 2016 |
Marcrom S, Thompson JW, McDonald A, Popple RA, Riley K, Markert JM, Willey CD, Bredel M, Fiveash JB. Stereotactic Hypofractionated Radiation Therapy for Intact Brain Metastases. International Journal of Radiation Oncology, Biology, Physics. 96: E120-E121. PMID 27673830 DOI: 10.1016/J.Ijrobp.2016.06.893 |
0.323 |
|
| 2016 |
Bauer DF, Pereboeva L, Gillespie GY, Cloud GA, Elzafarany O, Langford C, Markert JM, Jr LS. Effect of HSV-IL12 Loaded Tumor Cell-Based Vaccination in a Mouse Model of High-Grade Neuroblastoma. Journal of Immunology Research. 2016: 2568125. PMID 27610392 DOI: 10.1155/2016/2568125 |
0.345 |
|
| 2016 |
Patel DM, Foreman PM, Nabors LB, Riley KO, Gillespie GY, Markert JM. Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. Human Gene Therapy. Clinical Development. 27: 69-78. PMID 27314913 DOI: 10.1089/humc.2016.031 |
0.325 |
|
| 2016 |
Patel D, Foreman P, Nabors B, Riley K, Gillespie Y, Markert J. Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. Human Gene Therapy. Clinical Development. PMID 27231756 DOI: 10.1089/hum.2016.031 |
0.326 |
|
| 2016 |
Jackson JD, Markert JM, Li L, Carroll SL, Cassady KA. STAT1 and NFkappaB Inhibitors Diminish Basal Interferon Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST cells. Molecular Cancer Research : McR. PMID 26883073 DOI: 10.1158/1541-7786.Mcr-15-0427 |
0.309 |
|
| 2016 |
Cassady KA, Haworth KB, Jackson J, Markert JM, Cripe TP. To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses. Viruses. 8. PMID 26861381 DOI: 10.3390/V8020043 |
0.333 |
|
| 2016 |
Ring E, Moore B, Nan L, Etminan T, Markert J, Gillespie GY, Friedman G. Pcm-21Expression Of Immune Checkpoint Proteins In Patient-Derived Pediatric Brain Tumor Xenografts Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now080.21 |
0.404 |
|
| 2016 |
Ring E, Moore B, Nan L, Etminan T, Markert J, Gillespie GY, Friedman G. Pcm-09Comparison Of The Sensitivities Of Pediatric High-Grade Brain Tumor Versus Adult Glioblastoma Xenografts To Engineered Oncolytic Herpes Simplex Virotherapy Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now080.09 |
0.374 |
|
| 2016 |
Reddy A, Johnston J, Madan-Swain A, Fiveash J, Bag A, Gillespie GY, Markert J, Friedman G. EPT-10PHASE I CLINICAL TRIAL OF HSV G207 ALONE OR WITH A SINGLE RADIATION DOSE IN CHILDREN WITH RECURRENT SUPRATENTORIAL BRAIN TUMORS (NCT02457845) Neuro-Oncology. 18: iii25.5-iii26. DOI: 10.1093/Neuonc/Now069.09 |
0.368 |
|
| 2015 |
Arora K, Dawkins RL, Bauer DF, Palmer CA, Hackney JR, Markert JM. Intracranial blastomycotic abscess mimicking malignant brain neoplasm: Successful treatment with voriconazole and surgery. Surgical Neurology International. 6: 174. PMID 26673672 DOI: 10.4103/2152-7806.170025 |
0.324 |
|
| 2015 |
Cripe TP, Chen CY, Denton NL, Haworth KB, Hutzen B, Leddon JL, Streby KA, Wang PY, Markert JM, Waters AM, Gillespie GY, Beierle EA, Friedman GK. Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children. Molecular Therapy Oncolytics. 2. PMID 26436135 DOI: 10.1038/Mto.2015.15 |
0.411 |
|
| 2015 |
Friedman GK, Beierle EA, Gillespie GY, Markert JM, Waters AM, Chen CY, Denton NL, Haworth KB, Hutzen B, Leddon JL, Streby KA, Wang PY, Cripe TP. Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children. Molecular Therapy Oncolytics. 2. PMID 26436134 DOI: 10.1038/Mto.2015.16 |
0.416 |
|
| 2015 |
Friedman GK, Moore BP, Nan L, Kelly VM, Etminan T, Langford CP, Xu H, Han X, Markert JM, Beierle EA, Gillespie GY. Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses. Neuro-Oncology. PMID 26188016 DOI: 10.1093/Neuonc/Nov123 |
0.357 |
|
| 2015 |
Warram JM, de Boer E, Korb M, Hartman Y, Kovar J, Markert JM, Gillespie GY, Rosenthal EL. Fluorescence-guided resection of experimental malignant glioma using cetuximab-IRDye 800CW. British Journal of Neurosurgery. 1-9. PMID 26073144 DOI: 10.3109/02688697.2015.1056090 |
0.316 |
|
| 2015 |
Thomas EM, Popple RA, Markert JM, Fiveash JB. In Reply: Volumetric Arc Therapy (RapidArc) vs Gamma Knife Radiosurgery for Multiple Brain Metastases: Not Only a Dosimetric Issue. Neurosurgery. 77: E311. PMID 25951033 DOI: 10.1227/Neu.0000000000000797 |
0.33 |
|
| 2015 |
Bag AK, Kim H, Gao Y, Bolding M, Warren PP, Fathallah-Shaykh HM, Gurler D, Markert JM, Fiveash J, Beasley TM, Khawaja A, Friedman GK, Chapman PR, Nabors LB, Han X. Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas. Journal of Neuro-Oncology. 122: 585-93. PMID 25711673 DOI: 10.1007/S11060-015-1751-Z |
0.306 |
|
| 2015 |
Thomas EM, Popple RA, Markert JM, Fiveash JB. In reply: volumetric arc therapy (RapidArc) vs Gamma Knife radiosurgery for multiple brain metastases. Neurosurgery. 76: E353-4. PMID 25621987 DOI: 10.1227/Neu.0000000000000662 |
0.33 |
|
| 2015 |
Friedman GK, Nan L, Haas MC, Kelly VM, Moore BP, Langford CP, Xu H, Han X, Beierle EA, Markert JM, Cassady KA, Gillespie GY. γ₁34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia. Gene Therapy. 22: 348-55. PMID 25427614 DOI: 10.1038/Gt.2014.107 |
0.374 |
|
| 2015 |
Armstrong TS, Wen PY, Reardon DA, Phuphanich S, Aiken R, Landolfi JC, Curry WT, Zhu J, Glantz MJ, Peereboom DM, Markert J, LaRocca RV, O'Rourke D, Fink KL, Kim LJ, et al. Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107. Journal of Clinical Oncology. 33: 2036-2036. DOI: 10.1200/Jco.2015.33.15_Suppl.2036 |
0.316 |
|
| 2015 |
Wen P, Reardon D, Phuphanich S, Aiken R, Landolfi J, Curry W, Zhu J, Glantz M, Peereboom D, Markert J, Larocca R, O'Rourke D, Fink K, Kim L, Gruber M, et al. Imct-20Association Of Survival And Progression-Free Survival With Immune Response In Hla-A2+ Newly-Diagnosed Gbm Patients In Randomized Double-Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell (Dc) Immunotherapy With Ict-107 Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov218.20 |
0.313 |
|
| 2015 |
Waters AM, Stewart J, Friedman GK, Gillespie G, Markert JM, Beierle EA. Oncolytic Herpes Simplex Virus Decreased Rhabdomyosarcoma Cell Survival In Vitro and In Vivo Journal of the American College of Surgeons. 221: S105-S106. DOI: 10.1016/J.Jamcollsurg.2015.07.244 |
0.327 |
|
| 2014 |
Clark GM, McDonald AM, Nabors LB, Fathalla-Shaykh H, Han X, Willey CD, Markert JM, Guthrie BL, Bredel M, Fiveash JB. Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: the University of Alabama at Birmingham experience. Neuro-Oncology Practice. 1: 172-177. PMID 26034629 DOI: 10.1093/Nop/Npu028 |
0.397 |
|
| 2014 |
Jackson JD, McMorris AM, Roth JC, Coleman JM, Whitley RJ, Gillespie GY, Carroll SL, Markert JM, Cassady KA. Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines. Gene Therapy. 21: 984-90. PMID 25119379 DOI: 10.1038/Gt.2014.72 |
0.368 |
|
| 2014 |
Gebhardt BJ, Dobelbower MC, Ennis WH, Bag AK, Markert JM, Fiveash JB. Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. Radiation Oncology (London, England). 9: 130. PMID 24906388 DOI: 10.1186/1748-717X-9-130 |
0.347 |
|
| 2014 |
Cody JJ, Markert JM, Hurst DR. Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells. Plos One. 9: e92919. PMID 24651853 DOI: 10.1371/Journal.Pone.0092919 |
0.32 |
|
| 2014 |
Markert JM, Razdan SN, Kuo HC, Cantor A, Knoll A, Karrasch M, Nabors LB, Markiewicz M, Agee BS, Coleman JM, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Weichselbaum RR, et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1048-55. PMID 24572293 DOI: 10.1038/Mt.2014.22 |
0.397 |
|
| 2014 |
Kicielinski KP, Chiocca EA, Yu JS, Gill GM, Coffey M, Markert JM. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1056-62. PMID 24553100 DOI: 10.1038/Mt.2014.21 |
0.357 |
|
| 2014 |
Megison ML, Gillory LA, Stewart JE, Nabers HC, Mroczek-Musulman E, Waters AM, Coleman JM, Kelly V, Markert JM, Gillespie GY, Friedman GK, Beierle EA. Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors. Plos One. 9: e86843. PMID 24497984 DOI: 10.1371/Journal.Pone.0086843 |
0.4 |
|
| 2014 |
Wen PY, Reardon DA, Phuphanich S, Aiken R, Landolfi JC, Curry WT, Zhu J, Glantz MJ, Peereboom DM, Markert J, LaRocca RV, O'Rourke D, Fink KL, Kim LJ, Gruber ML, et al. A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients. Journal of Clinical Oncology. 32: 2005-2005. DOI: 10.1200/Jco.2014.32.15_Suppl.2005 |
0.361 |
|
| 2014 |
Wen P, Reardon D, Phuphanich S, Aiken R, Landolfi J, Curry W, Zhu J, Glantz M, Peereboom D, Markert J, Larocca R, O'Rourke D, Fink K, Kim L, Gruber M, et al. At-60A Randomized Double Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell (Dc) Vaccine Ict-107 Following Standard Treatment In Newly Diagnosed Patients With Gbm Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.59 |
0.316 |
|
| 2013 |
Gaston DC, Odom CI, Li L, Markert JM, Roth JC, Cassady KA, Whitley RJ, Parker JN. Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1. Plos One. 8: e81768. PMID 24312353 DOI: 10.1371/Journal.Pone.0081768 |
0.345 |
|
| 2013 |
Gillory LA, Megison ML, Stewart JE, Mroczek-Musulman E, Nabers HC, Waters AM, Kelly V, Coleman JM, Markert JM, Gillespie GY, Friedman GK, Beierle EA. Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma. Plos One. 8: e77753. PMID 24130898 DOI: 10.1371/Journal.Pone.0077753 |
0.422 |
|
| 2013 |
Whitley RJ, Markert JM. Viral therapy of glioblastoma multiforme. Proceedings of the National Academy of Sciences of the United States of America. 110: 11672-3. PMID 23836634 DOI: 10.1073/Pnas.1310253110 |
0.327 |
|
| 2013 |
Griguer CE, Cantor AB, Fathallah-Shaykh HM, Gillespie GY, Gordon AS, Markert JM, Radovanovic I, Clement-Schatlo V, Shannon CN, Oliva CR. Prognostic relevance of cytochrome C oxidase in primary glioblastoma multiforme. Plos One. 8: e61035. PMID 23593382 DOI: 10.1371/Journal.Pone.0061035 |
0.366 |
|
| 2013 |
Friedman GK, Raborn J, Kelly VM, Cassady KA, Markert JM, Gillespie GY. Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy. Frontiers in Oncology. 3: 28. PMID 23450706 DOI: 10.3389/Fonc.2013.00028 |
0.437 |
|
| 2013 |
Cody JJ, Markert JM, Hurst DR. Abstract B54: Treatment of breast cancer cells with histone deacetylase inhibitors increases the replication of an oncolytic herpes simplex virus Cancer Research. 73. DOI: 10.1158/1538-7445.Cec13-B54 |
0.355 |
|
| 2013 |
Clark GM, Stewart JG, Guthrie BL, Markert JM, Spencer SA, Riley KO, Meredith R, Wu X, Popple RA, Fiveash JB. Phase 1 Dose Escalation/De-escalation Study of Preoperative Stereotactic Radiosurgery for Brain Metastases: Preliminary Acute Toxicity and Dosimetric Analysis International Journal of Radiation Oncology Biology Physics. 87. DOI: 10.1016/J.Ijrobp.2013.06.708 |
0.303 |
|
| 2012 |
Cody JJ, Scaturro P, Cantor AB, Yancey Gillespie G, Parker JN, Markert JM. Preclinical evaluation of oncolytic δγ(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases. International Journal of Breast Cancer. 2012: 628697. PMID 23346408 DOI: 10.1155/2012/628697 |
0.368 |
|
| 2012 |
Markert JM. The role of early resection vs biopsy in the management of low-grade gliomas. Jama. 308: 1918-9. PMID 23099540 DOI: 10.1001/Jama.2012.14523 |
0.391 |
|
| 2012 |
Menendez JY, Bauer DF, Shannon CN, Fiveash J, Markert JM. Stereotactic radiosurgical treatment of brain metastasis of primary tumors that rarely metastasize to the central nervous system Journal of Neuro-Oncology. 109: 513-519. PMID 22870850 DOI: 10.1007/S11060-012-0916-2 |
0.369 |
|
| 2012 |
Friedman GK, Haas MC, Kelly VM, Markert JM, Gillespie GY, Cassady KA. Hypoxia Moderates γ(1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures. Translational Oncology. 5: 200-7. PMID 22741039 DOI: 10.1593/Tlo.12115 |
0.355 |
|
| 2012 |
Friedman GK, Cassady KA, Beierle EA, Markert JM, Gillespie GY. Targeting pediatric cancer stem cells with oncolytic virotherapy. Pediatric Research. 71: 500-10. PMID 22430386 DOI: 10.1038/Pr.2011.58 |
0.394 |
|
| 2012 |
Markert JM, Cody JJ, Parker JN, Coleman JM, Price KH, Kern ER, Quenelle DC, Lakeman AD, Schoeb TR, Palmer CA, Cartner SC, Gillespie GY, Whitley RJ. Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. Journal of Virology. 86: 5304-13. PMID 22379082 DOI: 10.1128/Jvi.06998-11 |
0.399 |
|
| 2012 |
Hawkins ES, Aiken R, Chandler J, Fink KL, Glantz MJ, Grewal J, Gruber ML, Kesari S, Landolfi JC, LaRocca RV, Lesser GJ, Markert J, Mayer TM, O'Rourke D, Peereboom DM, et al. A randomized, double‑blind, controlled phase IIb study of the safety and efficacy of ICT‑107 in newly diagnosed patients with glioblastoma multiforme following resection and chemoradiation. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps2107 |
0.381 |
|
| 2012 |
Gillory L, Haas M, Friedman G, Megison M, Stewart J, Parker J, Markert J, Gillespie G, Beierle E. Genetically Engineered Herpes Simplex Virus Expressing IL-12 Suppresses Murine Neuroblastoma Tumor Growth Journal of Surgical Research. 172: 196. DOI: 10.1016/J.Jss.2011.11.176 |
0.333 |
|
| 2012 |
Gillory LA, Megison ML, Stewart JE, Nabers HC, Friedman GK, Markert JM, Gillespie GY, Beierle EA. Oncolytic herpes simplex virus and radiation combination therapy results in a systemic immune response to inhibit neuroblastoma tumor growth Journal of the American College of Surgeons. 215: S69-S70. DOI: 10.1016/J.Jamcollsurg.2012.06.192 |
0.368 |
|
| 2011 |
Advani SJ, Markert JM, Sood RF, Samuel S, Gillespie GY, Shao MY, Roizman B, Weichselbaum RR. Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1. Gene Therapy. 18: 1098-102. PMID 21544094 DOI: 10.1038/Gt.2011.61 |
0.358 |
|
| 2011 |
Dobelbower MC, Burnett Iii OL, Nordal RA, Nabors LB, Markert JM, Hyatt MD, Fiveash JB. Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. Journal of Medical Imaging and Radiation Oncology. 55: 77-81. PMID 21382192 DOI: 10.1111/J.1754-9485.2010.02232.X |
0.304 |
|
| 2011 |
Bryant NL, Gillespie GY, Lopez RD, Markert JM, Cloud GA, Langford CP, Arnouk H, Su Y, Haines HL, Suarez-Cuervo C, Lamb LS. Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme. Journal of Neuro-Oncology. 101: 179-88. PMID 20532954 DOI: 10.1007/S11060-010-0245-2 |
0.338 |
|
| 2011 |
Gillory LA, Haas MC, Friedman GK, Stewart JE, Parker JN, Markert JM, Gillespie GY, Beierle EA. Combination treatment with genetically altered oncolytic herpes simplex virus and low-dose irradiation inhibits neuroblastoma tumor growth Journal of the American College of Surgeons. 213: S76. DOI: 10.1016/J.Jamcollsurg.2011.06.178 |
0.366 |
|
| 2010 |
Oliva CR, Nozell SE, Diers A, McClugage SG, Sarkaria JN, Markert JM, Darley-Usmar VM, Bailey SM, Gillespie GY, Landar A, Griguer CE. Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. The Journal of Biological Chemistry. 285: 39759-67. PMID 20870728 DOI: 10.1074/Jbc.M110.147504 |
0.308 |
|
| 2010 |
Nabors LB, Fiveash JB, Markert JM, Kekan MS, Gillespie GY, Huang Z, Johnson MJ, Meleth S, Kuo H, Gladson CL, Fathallah-Shaykh HM. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Archives of Neurology. 67: 313-9. PMID 20212229 DOI: 10.1001/Archneurol.2010.16 |
0.351 |
|
| 2010 |
Stewart JG, Harris AM, Fuller CD, Markert JM, Guthrie BL, Fiveash JB. Local Control and Long-term Survival for Patients with a Single Brain Metastasis Treated with Surgery followed by Stereotactic Radiosurgery to the Resection Cavity International Journal of Radiation Oncology Biology Physics. 78. DOI: 10.1016/J.Ijrobp.2010.07.419 |
0.315 |
|
| 2009 |
Karrasch M, Gillespie GY, Braz E, Liechty PG, Nabors LB, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Markert JM. Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2042. PMID 27964649 DOI: 10.1200/Jco.2009.27.15_Suppl.2042 |
0.354 |
|
| 2009 |
Kekan M, Fiveash J, Markert JM, Gillespie GY, Kuo H, Meleth S, Gladson CL, Nabors LB. A phase I study of ABT 510 and concurrent temozolamide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2023. PMID 27964603 DOI: 10.1200/Jco.2009.27.15_Suppl.2023 |
0.308 |
|
| 2009 |
Parker JN, Bauer DF, Cody JJ, Markert JM. Oncolytic viral therapy of malignant glioma. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 6: 558-69. PMID 19560745 DOI: 10.1016/J.Nurt.2009.04.011 |
0.416 |
|
| 2009 |
Friedman GK, Pressey JG, Reddy AT, Markert JM, Gillespie GY. Herpes simplex virus oncolytic therapy for pediatric malignancies. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1125-35. PMID 19367259 DOI: 10.1038/Mt.2009.73 |
0.422 |
|
| 2009 |
Kaliberova LN, Krendelchtchikova V, Harmon DK, Stockard CR, Petersen AS, Markert JM, Gillespie GY, Grizzle WE, Buchsbaum DJ, Kaliberov SA. CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma. Cancer Gene Therapy. 16: 794-805. PMID 19363468 DOI: 10.1038/Cgt.2009.23 |
0.337 |
|
| 2009 |
Bryant NL, Suarez-Cuervo C, Gillespie GY, Markert JM, Nabors LB, Meleth S, Lopez RD, Lamb LS. Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma. Neuro-Oncology. 11: 357-67. PMID 19211933 DOI: 10.1215/15228517-2008-111 |
0.337 |
|
| 2009 |
Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Gillespie GY. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 199-207. PMID 18957964 DOI: 10.1038/Mt.2008.228 |
0.426 |
|
| 2009 |
Advani S, Markert J, Sood R, Gillespie G, Roizman B, Weichselbaum R, Fiveash J. Increasing the Therapeutic Ratio of Oncolysis by Optimally Integrating Radiotherapy into the Replicative Cycle of Oncolytic HSV-1 for High Grade Gliomas International Journal of Radiation Oncology*Biology*Physics. 75: S558-S559. DOI: 10.1016/J.Ijrobp.2009.07.1276 |
0.306 |
|
| 2008 |
Pearson BE, Markert JM, Fisher WS, Guthrie BL, Fiveash JB, Palmer CA, Riley K. Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurgical Focus. 24: E3. PMID 18447742 DOI: 10.3171/Foc/2008/24/5/E3 |
0.374 |
|
| 2008 |
Forsyth P, Roldán G, George D, Wallace C, Palmer CA, Morris D, Cairncross G, Matthews MV, Markert J, Gillespie Y, Coffey M, Thompson B, Hamilton M. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 627-32. PMID 18253152 DOI: 10.1038/Sj.Mt.6300403 |
0.36 |
|
| 2008 |
Sawrie SM, Guthrie BL, Spencer SA, Nordal RA, Meredith RF, Markert JM, Cloud GA, Fiveash JB. Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone. International Journal of Radiation Oncology, Biology, Physics. 70: 181-6. PMID 17768015 DOI: 10.1016/J.Ijrobp.2007.05.084 |
0.377 |
|
| 2007 |
Radbill AE, Reddy AT, Markert JM, Wyss JM, Pike MM, Akella NS, Bharara N, Gillespie GY. Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain. Journal of Neurovirology. 13: 118-29. PMID 17505980 DOI: 10.1080/13550280601187177 |
0.424 |
|
| 2007 |
Shah AC, Parker JN, Gillespie GY, Lakeman FD, Meleth S, Markert JM, Cassady KA. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. Gene Therapy. 14: 1045-54. PMID 17429445 DOI: 10.1038/Sj.Gt.3302942 |
0.412 |
|
| 2007 |
Guffey MB, Parker JN, Luckett WS, Gillespie GY, Meleth S, Whitley RJ, Markert JM. Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Therapy. 14: 45-56. PMID 16990846 DOI: 10.1038/Sj.Cgt.7700978 |
0.448 |
|
| 2007 |
Fiveash JB, Sawrie SM, Guthrie BL, Spencer SA, Meredith RF, Markert JM, Nordal RA, Conry RM, Nabors LB. A phase II study of radiosurgery and temozolomide for patients with one to four brain metastases Journal of Clinical Oncology. 25: 2048-2048. DOI: 10.1200/Jco.2007.25.18_Suppl.2048 |
0.377 |
|
| 2007 |
Sawrie SM, Meredith RF, Spencer SA, Markert JM, Fiveash JB. HER2-neu status as a predictor of survival in patients with brain metastases from primary breast adenocarcinoma Journal of Clinical Oncology. 25: 1016-1016. DOI: 10.1200/Jco.2007.25.18_Suppl.1016 |
0.324 |
|
| 2006 |
Shah AC, Price KH, Parker JN, Samuel SL, Meleth S, Cassady KA, Gillespie GY, Whitley RJ, Markert JM. Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors. Journal of Virology. 80: 7308-15. PMID 16840311 DOI: 10.1128/Jvi.00725-06 |
0.41 |
|
| 2006 |
Vila-Carriles WH, Kovacs GG, Jovov B, Zhou ZH, Pahwa AK, Colby G, Esimai O, Gillespie GY, Mapstone TB, Markert JM, Fuller CM, Bubien JK, Benos DJ. Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells. The Journal of Biological Chemistry. 281: 19220-32. PMID 16704974 DOI: 10.1074/Jbc.M603100200 |
0.337 |
|
| 2006 |
Sawrie SM, Gurthrie BL, Spencer SA, Nordal RA, Meredith RF, Markert JM, Cloud GA, Fiveash JB. 2056 : Predictors of Distant Brain Recurrence for Newly Diagnosed Brain Metastases Treated with Stereotactic Radiosurgery Alone International Journal of Radiation Oncology Biology Physics. 66. DOI: 10.1016/J.Ijrobp.2006.07.459 |
0.321 |
|
| 2005 |
Hellums EK, Markert JM, Parker JN, He B, Perbal B, Roizman B, Whitley RJ, Langford CP, Bharara S, Gillespie GY. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro-Oncology. 7: 213-24. PMID 16053696 DOI: 10.1215/S1152851705000074 |
0.388 |
|
| 2005 |
Parker JN, Meleth S, Hughes KB, Gillespie GY, Whitley RJ, Markert JM. Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Therapy. 12: 359-68. PMID 15678154 DOI: 10.1038/Sj.Cgt.7700784 |
0.399 |
|
| 2004 |
Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, Kracher J, Grossman SA, Fisher JD, Carson K, Rosenblum M, Mikkelsen T, Olson J, Markert J, Rosenfeld S, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 958-66. PMID 15509513 DOI: 10.1016/J.Ymthe.2004.07.021 |
0.339 |
|
| 2004 |
Markert JM, Guffey MB, Manna DD, Buchsbaum DJ, Price KH, Langford CP, Gillespie GY. 1031. Improved Anti-Brain Tumor Efficacy of |[Delta]||[gamma]|134.5 HSV Expressing Cytosine Deaminase|[ast]| Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.976 |
0.414 |
|
| 2003 |
Shah AC, Benos D, Gillespie GY, Markert JM. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. Journal of Neuro-Oncology. 65: 203-26. PMID 14682372 DOI: 10.1023/B:Neon.0000003651.97832.6C |
0.416 |
|
| 2003 |
Markert J. Glioblastoma multiforme: introduction. Cancer Journal (Sudbury, Mass.). 9: 148. PMID 12952299 DOI: 10.1097/00130404-200305000-00002 |
0.445 |
|
| 2003 |
Berdiev BK, Xia J, McLean LA, Markert JM, Gillespie GY, Mapstone TB, Naren AP, Jovov B, Bubien JK, Ji HL, Fuller CM, Kirk KL, Benos DJ. Acid-sensing ion channels in malignant gliomas. The Journal of Biological Chemistry. 278: 15023-34. PMID 12584187 DOI: 10.1074/Jbc.M300991200 |
0.342 |
|
| 2001 |
Markert JM, Fuller CM, Gillespie GY, Bubien JK, McLean LA, Hong RL, Lee K, Gullans SR, Mapstone TB, Benos DJ. Differential gene expression profiling in human brain tumors. Physiological Genomics. 5: 21-33. PMID 11161003 DOI: 10.1152/Physiolgenomics.2001.5.1.21 |
0.323 |
|
| 2000 |
Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Therapy. 7: 867-74. PMID 10845725 DOI: 10.1038/Sj.Gt.3301205 |
0.394 |
|
| 2000 |
Markert JM, Gillespie GY, Weichselbaum RR, Roizman B, Whitley RJ. Genetically engineered HSV in the treatment of glioma: a review. Reviews in Medical Virology. 10: 17-30. PMID 10654002 DOI: 10.1002/(Sici)1099-1654(200001/02)10:1<17::Aid-Rmv258>3.0.Co;2-G |
0.32 |
|
| 1998 |
Andreansky S, He B, van Cott J, McGhee J, Markert JM, Gillespie GY, Roizman B, Whitley RJ. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Therapy. 5: 121-30. PMID 9536273 DOI: 10.1038/Sj.Gt.3300550 |
0.374 |
|
| 1996 |
Andreansky SS, He B, Gillespie GY, Soroceanu L, Markert J, Chou J, Roizman B, Whitley RJ. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proceedings of the National Academy of Sciences of the United States of America. 93: 11313-8. PMID 8876132 DOI: 10.1073/Pnas.93.21.11313 |
0.425 |
|
| 1993 |
Markert JM, Malick A, Coen DM, Martuza RL. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery. 32: 597-603. PMID 8386343 DOI: 10.1227/00006123-199304000-00016 |
0.381 |
|
| 1992 |
Markert JM, Coen DM, Malick A, Mineta T, Martuza RL. Expanded spectrum of viral therapy in the treatment of nervous system tumors. Journal of Neurosurgery. 77: 590-4. PMID 1326612 DOI: 10.3171/Jns.1992.77.4.0590 |
0.436 |
|
| 1991 |
Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (New York, N.Y.). 252: 854-6. PMID 1851332 DOI: 10.1126/Science.1851332 |
0.387 |
|
| Show low-probability matches. |